This new study of pediatric patients with type 1 diabetes from France and Belgium investigated the effectiveness of insulin delivery via closed-loop and open-loop systems. Closed-loop delivery of ...

While insulin pumps and continuous glucose monitors have improved the lives of many Type 1 diabetes patients, some still cannot maintain steady control. Implantable insulin pumps offer another option ...

Compared with sensor-augmented pump therapy, closed-loop insulin delivery increased glucose time in range and reduced hypoglycemia episodes but detracted from sleep quality. First-generation ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies*, insulin administration is manually controlled, while hybrid ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Closed-loop insulin pump therapy is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Young children with type 1 diabetes who ...

Children using advanced hybrid closed-loop insulin pumps achieved better glucose control, yet most failed to follow dietary and exercise guidelines, highlighting that technology alone cannot replace ...

Hybrid closed-loop systems are increasingly gaining recognition as a gold-standard option for diabetes management, and medtech makers are jumping at the opportunity to add their own artificial ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...

The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.